AQR Capital Management LLC Has $336,000 Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)

AQR Capital Management LLC grew its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) by 202.1% in the second quarter, HoldingsChannel.com reports. The fund owned 60,147 shares of the company’s stock after acquiring an additional 40,240 shares during the quarter. AQR Capital Management LLC’s holdings in Cytek Biosciences were worth $336,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of CTKB. Teachers Retirement System of The State of Kentucky grew its holdings in Cytek Biosciences by 16.8% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 116,937 shares of the company’s stock worth $1,067,000 after acquiring an additional 16,804 shares during the period. Vanguard Group Inc. grew its holdings in Cytek Biosciences by 7.3% during the 4th quarter. Vanguard Group Inc. now owns 11,890,700 shares of the company’s stock worth $108,443,000 after acquiring an additional 811,279 shares during the period. Texas Permanent School Fund Corp grew its holdings in Cytek Biosciences by 2.0% during the 1st quarter. Texas Permanent School Fund Corp now owns 86,601 shares of the company’s stock worth $581,000 after acquiring an additional 1,702 shares during the period. ProShare Advisors LLC grew its stake in shares of Cytek Biosciences by 7.6% in the 1st quarter. ProShare Advisors LLC now owns 23,941 shares of the company’s stock valued at $161,000 after buying an additional 1,687 shares during the period. Finally, Quadrature Capital Ltd acquired a new stake in shares of Cytek Biosciences in the 1st quarter valued at about $102,000. 69.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Piper Sandler reduced their target price on Cytek Biosciences from $8.50 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th.

Cytek Biosciences Price Performance

Shares of CTKB opened at $5.36 on Thursday. The stock has a 50-day moving average of $5.31 and a 200-day moving average of $5.78. The company has a market cap of $703.62 million, a PE ratio of -59.56 and a beta of 1.30. Cytek Biosciences, Inc. has a one year low of $3.80 and a one year high of $9.87.

Cytek Biosciences (NASDAQ:CTKB) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.05). Cytek Biosciences had a negative net margin of 8.88% and a negative return on equity of 3.75%. The business had revenue of $46.62 million during the quarter, compared to the consensus estimate of $49.02 million. During the same period in the previous year, the business posted ($0.02) EPS. Analysts expect that Cytek Biosciences, Inc. will post -0.11 EPS for the current fiscal year.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.